

Ra Pharmaceuticals, Inc.  
Form 4  
October 31, 2016

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Novartis Bioventures Ltd

2. Issuer Name and Ticker or Trading Symbol  
Ra Pharmaceuticals, Inc. [RARX]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
10/31/2016

\_\_\_ Director \_\_\_X\_\_\_ 10% Owner  
\_\_\_ Officer (give title below) \_\_\_ Other (specify below)

C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
\_\_\_ Form filed by One Reporting Person  
\_X\_ Form filed by More than One Reporting Person

CH-4002 BASEL, V8 0000000000

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
|                                 |                                      |  | Code                           | V   | Amount  | (A) or (D)   | Price                             |
| Common Stock                    | 10/31/2016                           |  | X                              |   | 62,914  | A  | 0.07<br>(2)                       |
| Common Stock                    | 10/31/2016                           |  | S(2)                           |   | 339   | D  | \$ 13<br>(2)                      |
| Common Stock                    | 10/31/2016                           |  | C                              |   | 1,389,797   | A  | (3) 1,452,372                     |
| Common Stock                    | 10/31/2016                           |  | C                              |   | 522,561   | A  | (4) 1,974,933                     |
|                                 | 10/31/2016                           |  | C                              |   | 486,104   | A  | (5) 2,461,037                     |

Edgar Filing: Ra Pharmaceuticals, Inc. - Form 4

Common  
Stock

Common Stock 10/31/2016 P 84,615 A \$ 13 2,545,652 D <sup>(1)</sup>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.** SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable Expiration Date                         | Title Amount Number Shares                                    |
| Warrants to Purchase Common Stock          | \$ 0.07 <sup>(2)</sup>                                 | 10/31/2016                           |  | X                              | 62,914  | <sup>(2)</sup> 04/01/2022                                | Common Stock 62,914   |
| Series A Preferred Stock                   | <sup>(3)</sup>   | 10/31/2016                           |  | C                              | 9,728,589   | <sup>(3)</sup> <sup>(3)</sup>                            | Common Stock 1,389,142  |
| Series B-1 Preferred Stock                 | <sup>(4)</sup>   | 10/31/2016                           |  | C                              | 3,657,932   | <sup>(4)</sup> <sup>(4)</sup>                            | Common Stock 522,500  |
| Series B-2 Preferred Stock                 | <sup>(5)</sup>   | 10/31/2016                           |  | C                              | 3,402,729   | <sup>(5)</sup> <sup>(5)</sup>                            | Common Stock 486,100  |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |         |       |
|--|---------------|-----------|---------|-------|
|  | Director      | 10% Owner | Officer | Other |
| Novartis Bioventures Ltd<br>C/O NOVARTIS INTERNATIONAL AG<br>WSJ-200.220 |               |           | X       |       |

CH-4002 BASEL, V8 0000000000

NOVARTIS AG  
LICHTSTRASSE 35  
BASEL, V8 CH 4056

X

## Signatures

/s/ Simon Zivi, Authorized Signatory /s/ Laurieann Chaikowsky, Authorized Signatory 10/31/2016

\_\_Signature of Reporting Person Date

/s/ Simon Zivi, Chairman /s/ Laurieann Chaikowsky, Authorized Signatory 10/31/2016

\_\_Signature of Reporting Person Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The board of directors of Novartis Bioventures Ltd. has sole voting and investment control and power over such securities. None of the members of its board of directors has individual voting or investment power with respect to such securities and each disclaims beneficial ownership of such securities. Novartis Bioventures Ltd. is an indirectly owned subsidiary of Novartis AG.

(2) The Warrants automatically exercised immediately prior to the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision, resulting in the Issuer withholding 339 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 62,575 shares, after deducting the aggregate exercise price.

(3) Each share of the Series A Preferred Stock is convertible into Common Stock on a 1-for-7 basis automatically upon the closing of the Issuer's initial public offering, and has no expiration date.

(4) Each share of the Series B-1 Preferred Stock is convertible into Common Stock on a 1-for-7 basis automatically upon the closing of the Issuer's initial public offering, and has no expiration date.

(5) Each share of the Series B-2 Preferred Stock is convertible into Common Stock on a 1-for-7 basis automatically upon the closing of the Issuer's initial public offering, and has no expiration date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.